Tim Boreham

Fragrant candle maker Dusk Group is expanding into the personal care category, to capture a younger customer base - and more males.

The local biotech sector is in recovery mode today, having fallen sharply on Friday after Trump's announcement of a 100% pharma tariff.

With extensive upcoming drug launches, NZ's Aft Pharmaceuticals is confident of hitting its $270 million revenue target by March 2027.

Starpharma has struck a headline $855m deal with Big Pharma Genentech to develop drugs that include the company's dendremer based candidates.

Emvision Medical Devices (ASX:EMV) hopes its Emu and First Responder devices will enable detection in the crucial first hour.

Imagion shares are on a tear after the US FDA said it had no objections to the proposed conduct of a phase II breast cancer imaging trial. 

Listed IT consultancy Atturra says AI means burgeoning data needs - and that means a growing risk of data breaches and other threats. 

By adopting FDA-endorsed endpoints that are easier to achieve, Dimerix has bolstered the chances of its pivotal kidney drug trial succeeding.

Three months after the US Sofdra launch, prescriptions have exceeded Botanix Pharmaceuticals' expectations. What are they sweating on next?

The ASX biotech sector dipped slightly in value in May, but stocks such as Medadvisor and Dimerix recorded lusty gains.